Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, ...

A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Fintel reports that on July 1, 2025, UBS initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy recommendation.

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

Kevin Tang's Concentra Biosciences lines up deal for flailing cancer cell therapy company Cargo Therapeutics — potentially ...